William Blair Expects Lower Earnings for ARS Pharmaceuticals

Key Points

• William Blair has revised its FY2025 earnings estimate for ARS Pharmaceuticals, projecting a loss of ($1.67) per share, down from a previous estimate of ($1.65) per share.
• ARS Pharmaceuticals' stock currently has a consensus rating of Buy from several analysts, with an average price target of $33.17.
• In recent insider activity, CEO Richard E. Lowenthal sold 50,000 shares at an average price of $14.49, resulting in a 4.01% decrease in his ownership of the stock.

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Analysts at William Blair decreased their FY2025 earnings per share (EPS) estimates for shares of ARS Pharmaceuticals in a report issued on Tuesday, September 30th. William Blair analyst L. Hanbury-Brown now anticipates that the company will earn ($1.67) per share for the year, down from their previous estimate of ($1.65). The consensus estimate for ARS Pharmaceuticals' current full-year earnings is ($0.55) per share. William Blair also issued estimates for ARS Pharmaceuticals' Q4 2025 earnings at ($0.40) EPS, Q1 2026 earnings at ($0.43) EPS, Q2 2026 earnings at ($0.21) EPS, Q3 2026 earnings at ($0.02) EPS, Q4 2026 earnings at ($0.10) EPS and FY2026 earnings at ($0.76) EPS.

SPRY has been the subject of several other reports. Roth Capital started coverage on ARS Pharmaceuticals in a research report on Thursday, September 4th. They issued a "buy" rating and a $40.00 target price for the company. Wall Street Zen downgraded ARS Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, July 26th. Finally, Raymond James Financial set a $32.00 target price on ARS Pharmaceuticals in a research report on Friday, September 26th. One analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $33.17.

ARS Pharmaceuticals Price Performance

ARS Pharmaceuticals stock opened at $10.09 on Thursday. The company has a current ratio of 6.17, a quick ratio of 5.98 and a debt-to-equity ratio of 0.37. The company has a market capitalization of $997.19 million, a PE ratio of -20.59 and a beta of 0.84. ARS Pharmaceuticals has a 12 month low of $9.34 and a 12 month high of $18.90. The stock has a 50-day moving average price of $13.20 and a two-hundred day moving average price of $14.21.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.05). ARS Pharmaceuticals had a negative return on equity of 21.85% and a negative net margin of 42.74%.The business had revenue of $15.72 million for the quarter, compared to the consensus estimate of $12.92 million.

Institutional Investors Weigh In On ARS Pharmaceuticals

Several large investors have recently added to or reduced their stakes in SPRY. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in ARS Pharmaceuticals by 5.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 247,314 shares of the company's stock worth $2,609,000 after purchasing an additional 12,777 shares during the period. Wealth Enhancement Advisory Services LLC grew its stake in ARS Pharmaceuticals by 4.6% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 60,294 shares of the company's stock worth $636,000 after purchasing an additional 2,670 shares during the period. Wellington Management Group LLP grew its stake in ARS Pharmaceuticals by 0.6% during the fourth quarter. Wellington Management Group LLP now owns 163,252 shares of the company's stock worth $1,722,000 after purchasing an additional 917 shares during the period. GAMMA Investing LLC grew its stake in ARS Pharmaceuticals by 4,319.7% during the first quarter. GAMMA Investing LLC now owns 3,359 shares of the company's stock worth $420,000 after purchasing an additional 3,283 shares during the period. Finally, Rhumbline Advisers grew its stake in ARS Pharmaceuticals by 7.1% during the first quarter. Rhumbline Advisers now owns 69,766 shares of the company's stock worth $878,000 after purchasing an additional 4,603 shares during the period. Institutional investors and hedge funds own 68.16% of the company's stock.

Insider Activity

In other news, CEO Richard E. Lowenthal sold 50,000 shares of the stock in a transaction dated Thursday, August 21st. The stock was sold at an average price of $14.49, for a total value of $724,500.00. Following the completion of the sale, the chief executive officer owned 1,196,494 shares of the company's stock, valued at approximately $17,337,198.06. This represents a 4.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Sarina Tanimoto sold 37,656 shares of the stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $14.09, for a total value of $530,573.04. Following the completion of the sale, the insider directly owned 1,247,447 shares of the company's stock, valued at approximately $17,576,528.23. The trade was a 2.93% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 112,500 shares of company stock valued at $1,615,759. Company insiders own 33.50% of the company's stock.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.